Newly diagnosed glioblastoma patients treated with Optune plus temozolomide were able to maintain quality of life for longer compared to those treated with temozolomide alone Data presented today as a late-breaking oral presentation at the American Society for Radiation Oncology’s 2017 Annual Meeting ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today results from its …

Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TTFields) at the American Society for Radiation Oncology’s (ASTRO) 2017 Annual Meeting, September 24 through September 27 in San Diego. A late-breaking oral presentation will focus …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that four data presentations on Tumor Treating Fields (TTFields) will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, September 8 through September 12 in Madrid, Spain. Among the highlights is a poster discussion of the overall survival and quality of life data …

Proposed trial design will examine the benefit of combining Optune with radiation therapy and temozolomide prior to the initiation of maintenance temozolomide ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, (Gemeinsamer Bundesausschuss or G-BA), has published its decision to support a clinical trial studying Optune for the treatment …